Healthcare Leaders Hub

🏠Home 📰News 📝Blog 🎬Videos Advertise Login

Your trusted source for pharmaceutical news, expert insights, and healthcare innovation.

💼𝕏 👥▶️

Content

📰News
📝Blog
🎬Videos

Company

🏠Home
🏢About Us
📧Contact

© 2026 PharmaVoice. All rights reserved. Empowering healthcare leaders.

Privacy Policy•Terms of Service

Pharma Tech

FDA approves Asahi Kasei’s Hovilpri for refractory HSV

Oct 12, 2026, 10:04 AM

Read Full Article → $FDA approves Asahi Kasei’s Hovilpri for refractory HSV$

Translate article text

Choose a language and wait for the translated text.

The US FDA has approved Asahi Kasei Therapeutics’ Hovilpri 100mg tablets to treat refractory mucocutaneous HSV lesions in immunocompromised adults.

FDA approves Asahi Kasei’s Hovilpri for refractory HSV | PharmaVoice